UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current and future treatment for alcoholic‐related liver diseases

Journal of gastroenterology and hepatology, 2023-08, Vol.38 (8), p.1218-1226

2023

Volltextzugriff (PDF)

Precision medicine in the era of potent antiviral therapy for chronic hepatitis B

Journal of gastroenterology and hepatology, 2022-07, Vol.37 (7), p.1191-1196

2022

Volltextzugriff (PDF)

Risk factors in nonalcoholic fatty liver disease

Clinical and molecular hepatology, 2023-02, Vol.29 (Suppl), p.S79-S85

2023

Volltextzugriff (PDF)

Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study

The journal of clinical endocrinology and metabolism, 2021-06, Vol.106 (6), p.1773-1782

2021

Volltextzugriff (PDF)

A need for patient-centered care in managing patients with liver cirrhosis

Clinical and Molecular Hepatology, 2021, 27(2), , pp.270-272

Yoon, Eileen L

2021

Volltextzugriff (PDF)

Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort

Journal of hepatology, 2024-06

2024

Volltextzugriff (PDF)

The chronological changes in the seroprevalence of anti-hepatitis A virus IgG from 2005 to 2019: Experience at four centers in the capital area of South Korea

Medicine (Baltimore), 2022-12, Vol.101 (48), p.e31639-e31639

2022

Volltextzugriff (PDF)

Correspondence on Letter regarding "Waiting for the changes after the adoption of steatotic liver disease"

Clinical and molecular hepatology, 2024-01, Vol.30 (1), p.126-128

2024

Volltextzugriff (PDF)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis

Gut and Liver, 2023, 17(1), , pp.8-9

2023

Volltextzugriff (PDF)

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Clinical and molecular hepatology, 2023-10, Vol.29 (4), p.1050-1051

2023

Volltextzugriff (PDF)

Waiting for the changes after the adoption of steatotic liver disease

Clinical and molecular hepatology, 2023-10, Vol.29 (4), p.844-850

2023

Volltextzugriff (PDF)

Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era

Hepatology research, 2022-03, Vol.52 (3), p.247-254

2022

Volltextzugriff (PDF)

Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease

Gut, 2022-05, Vol.71 (5), p.1035-1036

2022

Volltextzugriff (PDF)

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Clinical and Molecular Hepatology, 2020, 26(4), , pp.411-429

2020

Volltextzugriff (PDF)

Discordance diagnosis between B-mode ultrasonography and MRI proton density fat fraction for fatty liver

Scientific reports, 2023-09, Vol.13 (1), p.15557-15557, Article 15557

2023

Volltextzugriff (PDF)

Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

Hepatology (Baltimore, Md.), 2024-06, Vol.79 (6), p.1393-1400

2024

Volltextzugriff (PDF)

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Clinical gastroenterology and hepatology, 2022-06, Vol.20 (6), p.1343-1353.e16

2022

Volltextzugriff (PDF)

Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1041-1049.e3

2023

Volltextzugriff (PDF)

Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature

Gut and Liver, 2022, 16(3), , pp.319-320

2022

Volltextzugriff (PDF)

The Incidence and Care Cascade of the Hepatitis C Virus in Korea

Gut and Liver, 2023, 17(6), , pp.926-932

2023

Volltextzugriff (PDF)

Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Journal of hepatology, 2021-09, Vol.75 (3), p.725-726

2021

Volltextzugriff (PDF)

Letter to the Editor: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional second-tier test?

Hepatology (Baltimore, Md.), 2023-09, Vol.78 (3), p.E59-E60

2023

Volltextzugriff (PDF)

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1013-1022.e6

2023

Volltextzugriff (PDF)

Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis

Scientific reports, 2024-03, Vol.14 (1), p.7189-7189, Article 7189

2024

Volltextzugriff (PDF)

1 – 25 von 326

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(309)
Mit Volltextzugriff
(296)

Publikationsform

Sprache

Englisch
(272)
Koreanisch
(54)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Current and future treatment for alcoholic‐related liver diseases

Precision medicine in the era of potent antiviral therapy for chronic hepatitis B

Risk factors in nonalcoholic fatty liver disease

Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study

A need for patient-centered care in managing patients with liver cirrhosis

Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort

The chronological changes in the seroprevalence of anti-hepatitis A virus IgG from 2005 to 2019: Experience at four centers in the capital area of South Korea

Correspondence on Letter regarding "Waiting for the changes after the adoption of steatotic liver disease"

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Waiting for the changes after the adoption of steatotic liver disease

Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era

An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Discordance diagnosis between B-mode ultrasonography and MRI proton density fat fraction for fatty liver

Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy

Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature

The Incidence and Care Cascade of the Hepatitis C Virus in Korea

Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

Letter to the Editor: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional second-tier test?

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis

Suchergebnisse filtern